ʻaoʻao_banner

Mechanism of Platelet Rich Plasma (PRP) Therapy Promoting Tissue Healing

I kēia lā, ʻike mua ʻia ka manaʻo i kapa ʻia ʻo PRP ma ke kahua o ka hematology i nā makahiki 1970.Ua hoʻokumu nā Hematologists i ka huaʻōlelo PRP i nā makahiki i hala aku nei e wehewehe i ka plasma i loaʻa mai ka helu platelet i ʻoi aku ka kiʻekiʻe ma mua o ke kumu waiwai o ke koko peripheral.ʻOi aku ma mua o ʻumi mau makahiki ma hope, ua hoʻohana ʻia ʻo PRP i ka hana maxillofacial ma ke ʻano he platelet rich fibrin (PRF).He waiwai koʻikoʻi ka maʻiʻo o ka fibrin i loko o kēia derivative PRP ma muli o kona adhesiveness a me nā ʻano kūlana paʻa, ʻoiai ʻo PRP i hoʻomau i nā waiwai anti-inflammatory a hoʻoulu i ka hoʻonui ʻana o nā cell.ʻO ka hope, ma kahi o nā 1990s, ua hoʻomaka ka PRP e lilo i mea kaulana.ʻO ka hope, ua hoʻololi ʻia kēia ʻenehana i nā ʻoihana lapaʻau ʻē aʻe.Mai ia manawa mai, ua aʻo nui ʻia kēia ʻano biology maikaʻi a hoʻohana ʻia i ka mālama ʻana i nā ʻeha musculoskeletal like ʻole o nā poʻe haʻuki ʻoihana, kahi i hoʻolaha nui ai i kona manaʻo nui i ka media.Ma waho aʻe o ka maikaʻi i ka lāʻau orthopedic a me ka lāʻau haʻuki, hoʻohana ʻia ʻo PRP i ka ophthalmology, gynecology, urology a me ka cardiology, pediatrics a me nā ʻoki plastik.I nā makahiki i hala iho nei, ua hoʻomaikaʻi ʻia ʻo PRP e ka poʻe dermatologists no kona hiki ke mālama i nā maʻi ʻili, ka hoʻoponopono ʻili, ka hoʻolaʻa hou ʻana o ka ʻiʻo, ka ʻili hou a me ka lilo o ka lauoho.

PRP

Ke noʻonoʻo nei i ka hiki i ka PRP ke hoʻoponopono pololei i nā kaʻina hana ho'ōla a me ka inflammatory, pono e hoʻolauna i ka cascade ho'ōla ma ke ʻano he kuhikuhi.Hoʻokaʻawale ʻia ke kaʻina hana ho'ōla i nā pae ʻehā: hemostasis;ʻAha;ʻO ka hoʻonui ʻana o ke kelepona a me ka matrix, a ma hope o ka hoʻoponopono hou ʻana.

 

Hoʻōla ʻiʻo

Hoʻoulu ʻia ka hopena o ka hoʻōla ʻana o ka ʻiʻo, kahi e alakaʻi ai i ka platelet aggregation Ka hoʻokumu ʻana o nā clots a me ka hoʻomohala ʻana o ka matrix extracellular matrix (ECM).A laila, pili nā platelets i ka collagen i hōʻike ʻia a me ka protein ECM, e hoʻomaka ana i ka hoʻokuʻu ʻana o nā molekole bioactive i loko o nā a-granules.Loaʻa i nā platelets nā ʻano molekole bioactive, me nā mea ulu, nā mea chemotherapy a me nā cytokines, a me nā mea hoʻolaha proinflammatory, e like me prostaglandin, prostate cyclin, histamine, thromboxane, serotonin a me bradykinin.

ʻO ka pae hope o ke kaʻina hana ho'ōla e pili ana i ka hoʻoponopono hou ʻana o ka ʻeha.Hoʻoponopono paʻa ʻia ka hoʻoponopono hou ʻana o ka ʻili e hoʻokumu i kahi kaulike ma waena o nā hopena anabolic a me catabolic.Ma kēia pae, hoʻoulu ka platelet-derived growth factor (PDGF) a me ka transforming growth factor (TGF- β) Fibronectin a me fibronectin e hoʻoulu i ka hoʻonui a me ka neʻeʻana o nā fibroblasts, a me ka synthesis o nā mea ECM.Eia nō naʻe, ʻo ka manawa o ka hōʻeha ʻana o ka ʻeha e hilinaʻi nui ʻia i ka paʻakikī o ka ʻeha, nā hiʻohiʻona o kēlā me kēia kanaka a me ka hiki ke ho'ōla kūikawā o ka ʻiʻo ʻeha.Hiki i kekahi mau mea pathophysiological a me ka metabolic ke hoʻopili i ke kaʻina hana ho'ōla, e like me ka ischemia kiko, hypoxia, ka maʻi, ka ulu ʻole o ka ulu ʻana, a me nā maʻi pili i ka metabolic syndrome.

Hoʻopilikia ka microenvironment proinflammatory i ka hana ho'ōla.ʻOi aku ka paʻakikī o ka hana protease kiʻekiʻe e kāohi i ka hana kūlohelohe o ka ulu ulu (GF).Ma waho aʻe o kāna mau mitotic, angiogenic a me chemotactic waiwai, ʻo PRP kekahi kumu waiwai o nā kumu ulu.Hiki i kēia mau biomolecules ke kū'ē i nā hopena pōʻino i loko o nāʻiʻo inflammatory ma o ka hoʻomaluʻana i ka hoʻonuiʻana i ka mumū a me ka hoʻokumuʻana i nā mea hoʻoulu anabolic.Ke noʻonoʻo nei i kēia mau hiʻohiʻona, hiki i nā mea noiʻi ke loaʻa i ka mana nui i ka mālama ʻana i nā ʻeha paʻakikī.

ʻO nā maʻi he nui, ʻoi aku ka nui o ke ʻano musculoskeletal, hilinaʻi nui i nā huahana olaola e hoʻoponopono i ke kaʻina hana inflammatory, e like me PRP no ka mālama ʻana i ka osteoarthritis.I kēia hihia, hilinaʻi ke olakino o ka cartilage articular i ke kaulike pololei o nā hopena anabolic a me catabolic.Me kēia kumumanaʻo i ka noʻonoʻo, hiki i ka hoʻohana ʻana i kekahi mau mea ola ola maikaʻi ke hōʻoia i ka holomua i ka loaʻa ʻana o kahi kaulike olakino.PRP no ka mea e hoʻokuʻu ana i nā platelets α- Hoʻohana nui ʻia nā mea ulu i loko o nā granule e hoʻoponopono i ka hiki ke hoʻololi i ka ʻiʻo, e hōʻemi ana i ka ʻeha.ʻO ka ʻoiaʻiʻo, ʻo kekahi o nā pahuhopu nui o ka mālama ʻana i ka PRP ʻo ka hoʻopau ʻana i ka microenvironment inflammatory a catabolic a hoʻoikaika i ka hoʻololi ʻana i nā lāʻau anti-inflammatory.Ua hōʻike mua nā mea kākau ʻē aʻe e hoʻonui ana ka thrombin i ka PRP i ka hoʻokuʻu ʻana o kekahi mau molekala olaola.ʻO kēia mau mea e pili ana i ka hepatocyte growth factor (HGF) a me ka tumor necrosis factor (TNF-α) 、 Transforming growth factor beta1 (TGF- β 1), vascular endothelial growth factor (VEGF) a me ka epidermis Growth factor (EGF).Ua hōʻike ʻia nā haʻawina ʻē aʻe i ka PRP e hāpai i ka piʻi ʻana o ke ʻano ii collagen a aggrecan mRNA pae, ʻoiai e hōʻemi ana i ka inhibition o ka interleukin cytokine pro-inflammatory - (IL) 1 ma luna o lākou.Ua manaʻo ʻia ma muli o ka HGF a me TNF-α [28] PRP hiki ke kōkua i ka hoʻokumu ʻana i ka hopena anti-inflammatory.ʻO kēia mau hoʻomākaukau molekala ʻelua e hōʻemi i ka mea nuklea kappaB (NF-κВ) Anti activation haʻawina a me ka ʻōlelo;ʻO ka lua, ma o ka'ōlelo TGF-β 1 ka mea e pale ai i ka chemotaxis monocyte, a laila e kū'ē i ka hopena TNF-α i ka transactivation o nā chemokines.He mea nui ka HGF i ka hopena anti-inflammatory i hoʻokomo ʻia e PRP.Hoʻopau kēia cytokine anti-inflammatory ikaika i ke ala hōʻailona NF-κ B a me ka hōʻike cytokine proinflammatory e kāohi i ka pane ʻana.Eia hou, hiki i ka PRP ke hoʻemi i ke kiʻekiʻe o ka nitric oxide (NO).No ka laʻana, i ka cartilage articular, ua hōʻike ʻia ka piʻi ʻana o ka NO ka hoʻonui ʻana i ka collagen synthesis a me ka hoʻoulu ʻana i ka chondrocyte apoptosis, ʻoiai e hoʻonui ana i ka synthesis o matrix metalloproteinases (MMPs), a laila e hoʻoikaika i ka hoʻololi ʻana o ka catabolism.Ma nā ʻōlelo o ka degeneration cell, manaʻo ʻia ʻo PRP e hiki ke hoʻopololei i ka autophagy o nā ʻano kelepona kikoʻī.I ka hiki ʻana i ke kūlana ʻelemakule hope loa, nalowale kekahi mau pūʻulu kelepona i ka hiki o ke kūlana static a me ka hana hou ʻana iā lākou iho.Eia naʻe, ua hōʻike ʻia nā haʻawina hou e hiki ke hoʻohuli maikaʻi ka mālama PRP i kēia mau kūlana pōʻino.Ua hōʻoia ʻo Moussa a me nā hoahana e hiki i ka PRP ke hoʻoulu i ka pale o nā chondrocytes ma o ka hoʻonui ʻana i ka autophagy a me nā hōʻailona anti-inflammatory, ʻoiai e hōʻemi ana i ka apoptosis o ka cartilage osteoarthritis kanaka.ʻO Garcia Pratt et al.Ua hōʻike ʻia ua hoʻoholo ʻo autophagy i ka hoʻololi ʻana ma waena o ka hoʻomaha a me ka hopena o ka ʻelemakule o nā ʻiʻo stem cell.Manaʻo nā mea noiʻi, i loko o ka vivo, ʻo ka normalization o ka autophagy i hoʻohui ʻia e pale i ka hōʻiliʻili ʻana o ka pōʻino intracellular a pale i ka ʻelemakule a me ka emi ʻana o ka hana o nā cell satellite.ʻOiai i ka wā kahiko o nā pūnaewele kino kanaka, e like me kēia manawa, ua hana nui ʻo Parrish lāua ʻo Rodes i nā haʻawina nui, e hōʻike hou ana i ka mana anti-inflammatory o PRP.I kēia manawa, ʻo ka manaʻo e pili ana i ka pilina ma waena o nā platelets a me nā neutrophils.I kā lākou noiʻi ʻana, ua wehewehe ka poʻe noiʻi e hoʻopili ʻia nā platelets i hoʻokuʻu ʻia e ka arachidonic acid e nā neutrophils a hoʻololi ʻia i leukotrienes a me nā prostaglandins, nā mea i ʻike ʻia i nā molekele inflammatory.Eia nō naʻe, hiki i ka platelet neutrophil pāʻani ke hoʻololi i ka leukotriene i lipoproteins, i hōʻike ʻia i kahi protein anti-inflammatory maikaʻi e hiki ke kaupalena i ka hoʻāla ʻana o nā neutrophils a pale i ka dialysis, a hoʻoikaika i ka hoʻoilina i ka pae hope o ka cascade ho'ōla.

Hoʻopilikia ka microenvironment proinflammatory i ka hana ho'ōla.ʻOi aku ka paʻakikī o ka hana protease kiʻekiʻe e kāohi i ka hana kūlohelohe o ka ulu ulu (GF).Ma waho aʻe o kāna mau mitotic, angiogenic a me chemotactic waiwai, ʻo PRP kekahi kumu waiwai o nā kumu ulu.Hiki i kēia mau biomolecules ke pale aku i nā hopena ʻino i loko o nā ʻiʻo inflammatory ma o ka hoʻomalu ʻana i ka hoʻonui ʻana a me ka hoʻokumu ʻana i ka hoʻoulu anabolic.

 

Pūnaehana Pūnaewele

He kuleana koʻikoʻi nā Cytokines i ka PRP i ka hoʻoponopono ʻana i ke kaʻina hana o ka hoʻoponopono ʻana i ka ʻiʻo a me ka hoʻoponopono ʻana i ka pōʻino inflammatory.ʻO nā cytokine anti-inflammatory he ʻano nui o nā molekole biochemical e hoʻoponopono i ka pane o nā cytokines proinflammatory, ka mea i hoʻoulu ʻia e nā macrophages i hoʻāla ʻia.Hoʻopili nā cytokine anti-inflammatory me nā mea hoʻopaneʻe cytokine kikoʻī a me nā mea loaʻa cytokine soluble e hoʻoponopono i ka mumū.Interleukin (IL) - 1 receptor antagonists, IL-4, IL-10, IL-11 a me IL-13 i hoʻokaʻawale ʻia e like me nā lāʻau anti-inflammatory nui, cytokines.Wahi a nā ʻano ʻeha like ʻole, kekahi mau cytokines, e like me interferon, leukemia inhibitory factor, TGF- β A me IL-6, hiki ke hōʻike i nā hopena proinflammatory a anti-inflammatory.Loaʻa iā TNF-α, IL-1 a me IL-18 kekahi mau cytokine receptors, hiki ke kāohi i ka hopena proinflammatory o nā protein ʻē aʻe [37].ʻO IL-10 kekahi o nā cytokine anti-inflammatory maikaʻi loa, hiki iā ia ke hoʻoponopono i nā cytokine proinflammatory e like me IL-1, IL-6 a me TNF-α, A hiki ke hoʻoponopono i nā mea anti-inflammatory.He kuleana koʻikoʻi kēia mau hana anti regulatory i ka hana a me ka hana o nā cytokines proinflammatory.Eia kekahi, hiki i kekahi mau cytokines ke hoʻoulu i nā pane hōʻailona kikoʻī e hoʻoulu i nā fibroblasts, he mea koʻikoʻi no ka hoʻoponopono ʻana i nā kiko.ʻO ka cytokine inflammatory TGF β 1, IL-1 β, IL-6, IL-13 a me IL-33 e hoʻoulu i nā fibroblasts e hoʻokaʻawale i nā myofibroblasts a hoʻomaikaʻi i ka ECM [38].Ma ka huli, fibroblasts huna cytokine TGF-β, IL-1 β, IL-33, CXC a me CC chemokines paipai inflammatory pane ma ka ho'ā 'ana a me ka recruiting immune cell e like me macrophages.ʻO kēia mau pūnaewele inflammatory e pāʻani i nā hana he nui i ka ʻeha, ka mea nui ma ka hoʻolaha ʻana i ka ʻeha ʻeha - a me ka biosynthesis o chemokines, metabolites a me nā mea ulu, he mea koʻikoʻi no ke kūkulu hou ʻana i nā ʻiʻo hou.No laila, he kuleana koʻikoʻi nā cytokines i ka PRP i ka hoʻoulu ʻana i ke ʻano o ka cell mediated immune response a me ka hoʻoikaika ʻana i ka regression o ka pae inflammatory.ʻO kaʻoiaʻiʻo, ua koho kekahi poʻe noiʻi i kēia kaʻina hana ma ke ʻano he "regenerative inflammation", e hōʻike ana i ka pae inflammatory, ʻoiai ka hopohopo o ka mea maʻi, he hana kūpono a koʻikoʻi no ka hopena kūleʻa o ke kaʻina hana hoʻoponopono, me ka noʻonoʻo ʻana i ka epigenetic mechanical e hōʻailona ai ka mumū. hoʻoikaika i ka plasticity cell.

ʻO ke kuleana o nā cytokines i ka ʻili o ka ʻili fetal he mea nui ia i ka noiʻi ʻana i ka lāʻau lapaʻau regenerative.ʻO ka ʻokoʻa ma waena o nā ʻano hana hoʻōla o ka fetal a me ke kanaka makua, ʻo ia ka hoʻi ʻana o nā ʻiʻo fetal i hōʻino ʻia i ko lākou kūlana mua e like me ka makahiki fetal a me nā ʻano kiko pili.I loko o ke kanaka, hiki i ka ʻili fetal ke hoʻōla hou i loko o 24 mau pule, ʻoiai i nā pākeke, hiki i ka hoʻōla ʻana i ka ʻeha ke alakaʻi i ka hoʻokumu ʻana i ka ʻili.E like me kā mākou i ʻike ai, i hoʻohālikelike ʻia me nā ʻiʻo olakino, ua hoʻemi nui ʻia nā ʻano mechanical o nā ʻiʻo scar, a ua kaupalena ʻia kā lākou mau hana.Hāʻawi ʻia ka manaʻo nui i ka cytokine IL-10, ka mea i ʻike nui ʻia i loko o ka wai amniotic a me ka ʻili fetal, a ua hōʻike ʻia e pāʻani i kahi hana i ka hoʻoponopono ʻole ʻana o ka ʻili fetal, i hāpai ʻia e ka hopena pleiotropic o ka cytokine.ZgheibC et al.Ua aʻo ʻia ka hoʻololi ʻana o ka ʻili fetal i nā ʻiole transgenic knockout (KO) IL-10 a me nā ʻiole hoʻomalu.Ua hōʻike ʻia nā ʻiole IL-10KO i nā hōʻailona o ka ʻulaʻula a me ka hoʻokumu ʻana o ka ʻili a puni nā grafts, ʻoiai ʻo nā grafts i ka pūʻulu hoʻomalu i hōʻike ʻole i nā loli koʻikoʻi i nā waiwai biomechanical a ʻaʻohe hoʻōla ʻala.

ʻO ke koʻikoʻi o ka hoʻoponopono ʻana i ke kaulike maʻalahi ma waena o ka hōʻike ʻana o nā cytokine anti-inflammatory a pro-inflammatory ʻo ia ka mea hope, i ka wā i hoʻonui ʻia ai, e hoʻouna i nā hōʻailona o ka hōʻino ʻana o ka cell ma ka hōʻemi ʻana i ka hōʻike o kekahi mau genes.No ka laʻana, i ka lāʻau musculoskeletal, IL-1 β Down e hoʻoponopono i ka SOX9, nona ke kuleana no ka hoʻomohala ʻana i ka cartilage.Hoʻopuka ʻo SOX9 i nā kumu transcription koʻikoʻi no ka hoʻomohala ʻana i ka cartilage, hoʻoponopono i ke ʻano II collagen alpha 1 (Col2A1), a nona ke kuleana no ka hoʻopili ʻana i nā genes collagen type II.IL-1 β ʻO ka hope, ua hoʻemi ʻia ka ʻōlelo o Col2A1 a me aggrecan.Eia nō naʻe, ʻo ka mālama ʻana me nā huahana waiwai platelet ua hōʻike ʻia e kāohi i ka IL-1 β He mea hiki ke hoʻopili i ka lāʻau lapaʻau e mālama i ka hōʻike ʻana o nā genes coding collagen a hoʻemi i ka apoptosis o nā chondrocytes i hoʻoulu ʻia e nā cytokines proinflammatory.

Hoʻoulu Anabolic: Ma waho aʻe o ka hoʻoponopono ʻana i ke kūlana inflammatory o ka ʻiʻo i hōʻino ʻia, komo pū nā cytokines i ka PRP i ka hopena anabolic ma o ka pāʻani ʻana i kā lākou mau kuleana o ka mitosis, ka mea hoʻonaninani a me ka hoʻonui.He haʻawina in vitro kēia i alakaʻi ʻia e Cavallo et al.E aʻo i nā hopena o nā PRP like ʻole ma nā chondrocytes kanaka.Ua ʻike nā mea noiʻi i nā huahana PRP me nā platelet haʻahaʻa haʻahaʻa a me nā ʻano leukocyte e hoʻoulu i ka hana chondrocyte maʻamau, kahi kūpono i ka hoʻolaha ʻana i kekahi mau mīkini kelepona o ka pane anabolic.No ka laʻana, ʻike ʻia ka hōʻike ʻana o ka collagen type ii a me nā glycans aggregating.I ka hoʻohālikelike ʻana, ʻike ʻia nā kiʻekiʻe o nā platelets a me nā leukocytes e hoʻoulu i nā ala hōʻailona kelepona e pili ana i nā cytokines like ʻole.Manaʻo nā mea kākau e pili ana kēia ma muli o ka nui o nā keʻokeʻo keʻokeʻo keʻokeʻo i kēia ʻano PRP.ʻO kēia mau pūnaewele ke kuleana no ka hoʻonui ʻana i ka hōʻike ʻana o kekahi mau mea ulu, e like me VEGF, FGF-b, a me nā interleukins IL-1b a me IL-6, ʻo ia paha ka mea e hoʻoulu ai iā TIMP-1 a me IL-10.I nā huaʻōlelo ʻē aʻe, i hoʻohālikelike ʻia me ka ʻano PRP "ʻino", ʻo ka hui PRP waiwai i nā platelets a me nā keʻokeʻo keʻokeʻo e hoʻoikaika i ka invasiveness pili o nā chondrocytes.

ʻO kahi haʻawina i hoʻolālā ʻia e Schnabel et al.ua hoʻolālā ʻia e loiloi i ka hana o nā biomaterial autologous i loko o ka ʻiʻo tendon lio.Ua hōʻiliʻili nā mea kākau i nā hōʻailona koko a me nā tendon mai ʻeono mau lio ʻōpio makua (2-4 mau makahiki), a ua kālele i ke aʻo ʻana i ke ʻano hōʻike gene, DNA a me collagen maʻiʻo o nā tendon explants o flexor digitorum superficialis o nā lio i moʻomeheu ʻia i loko o ka ʻenehana PRP. a i ʻole nā ​​huahana koko ʻē aʻe.Ua hoʻoulu ʻia nā mea hoʻokalakupua i ke koko, plasma, PRP, platelet deficient plasma (PPP) a i ʻole bone marrow aspirates (BMA), a ua hoʻohui ʻia nā amino acids i 100%, 50% a i ʻole 10% serum free DMEM.I ka holo ʻana i ka loiloi biochemical kūpono ma hope o…, ua ʻike nā mea noiʻi ua ʻoi aku ka kiʻekiʻe o ka manaʻo o PDGF-BB a me PDGF-1 ma PRP ma mua o nā huahana koko ʻē aʻe i hoʻāʻo ʻia.Eia kekahi, ua hōʻike ʻia nā ʻiʻo tendon i hoʻoulu ʻia ma 100% PRP medium i ka hoʻonui ʻana i ka hōʻike ʻana o ka matrix proteins COL1A1, COL3A1 a me COMP, akā ʻaʻole i hoʻonui i nā enzyme catabolic MMPs3 a me 13. ʻO ka liʻiliʻi ma ke ʻano o ka hoʻolālā tendon, kākoʻo kēia haʻawina in vivo i ka hoʻohana ʻana o autolo - he hua koko gouty, a i ʻole PRP, no ka mālama ʻana i ka tendinitis mammalian nui.

ʻO Chen et al.Ua kūkākūkā hou ʻia ka hopena hou o ka PRP.I kā lākou mau haʻawina mua, ua hōʻoia ka poʻe noiʻi, ma kahi o ka hoʻonui ʻana i ka hoʻokumu ʻana i ka cartilage, hoʻolaha pū ka PRP i ka hoʻonui ʻana o ka synthesis ECM a kāohi i ka hopena inflammatory o ka cartilage articular a me ka nucleus pulposus.Hiki i ka PRP ke hoʻoikaika i ka TGF ma o ka phosphorylation o Smad2 / 3-β Signal alahele he mea nui i ka ulu ʻana o ka cell a me ka ʻokoʻa.Eia kekahi, ua manaʻoʻiʻo ʻia ʻo nā fibrin clots i hoʻokumu ʻia ma hope o ka hoʻoulu ʻana o PRP e hāʻawi i kahi ʻano ʻekolu-dimensional paʻa, e hiki ai i nā cell ke hoʻopili, hiki ke alakaʻi i ke kūkulu ʻana i nā ʻiʻo hou.

Ua hāʻawi nui nā mea noiʻi ʻē aʻe i ka mālama ʻana i nā maʻi ʻili maʻi ma ke kahua o ka dermatology.He mea nui no hoi keia.No ka laʻana, ʻo ka noiʻi i alakaʻi ʻia e Hessler lāua ʻo Shyam ma 2019 e hōʻike ana he waiwai nui ka PRP ma ke ʻano he hiki ke kūpono a maikaʻi hoʻi i ka mālama ʻana, ʻoiai ʻo ka maʻi maʻi maʻi kūʻē i ka lāʻau e lawe mau ana i ke kaumaha waiwai i ka mālama olakino.ʻO ka mea nui, ʻo ka maʻi maʻi maʻi maʻi wāwae he pilikia olakino koʻikoʻi, kahi e maʻalahi ai ka ʻoki ʻia ʻana o nā lālā.ʻO kahi haʻawina i paʻi ʻia e Ahmed et al.i ka 2017 hōʻike i ka autologous PRP gel hiki ke hoʻoulu i ka hōʻeha ʻana i nā maʻi me ka maʻi maʻi maʻi maʻi wāwae wāwae ma o ka hoʻokuʻu ʻana i nā kumu ulu e pono ai, a laila e hoʻomaikaʻi nui i ka helu ho'ōla.Pēlā nō, nānā a kūkākūkā ʻo Gonchar a me nā hoa hana i ka hiki ke hoʻoponopono hou ʻia o PRP a me ka ulu ʻana o ka cocktails i ka hoʻomaikaʻi ʻana i ka mālama ʻana i nā maʻi ʻeha wāwae maʻi diabetes.Ua manaʻo ka poʻe noiʻi e hiki ke hoʻohana ʻia ka hoʻohana ʻana i nā mea hoʻohui ulu e hiki ke hoʻomaikaʻi i nā pono o ka hoʻohana ʻana i ka PRP a me ka mea ulu hoʻokahi.No laila, ke hoʻohālikelike ʻia me ka hoʻohana ʻana i ka mea ulu hoʻokahi, hiki i ka hui pū ʻana o PRP a me nā hoʻolālā lapaʻau ʻē aʻe ke hoʻoikaika nui i ka ho'ōla ʻana i nā maʻi maʻi maʻi.

 

Fibrin

Lawe nā platelets i kekahi mau mea pili i ka ʻōnaehana fibrinolytic, hiki ke hoʻoponopono a hoʻohaʻahaʻa paha i ka hopena fibrinolytic.ʻO ka pilina manawa a me ka hāʻawi pili ʻana o nā ʻāpana hematological a me ka hana platelet i ka hoʻohaʻahaʻa ʻana i ka clot he pilikia ia e pono ai ke kūkākūkā nui i ke kaiāulu.Hōʻike ka puke moʻolelo i nā haʻawina he nui wale i nā platelets, i kaulana no ko lākou hiki ke hoʻopili i ke kaʻina hana ho'ōla.ʻOiai ka nui o nā haʻawina koʻikoʻi, ʻo nā mea hematological ʻē aʻe, e like me nā kumu coagulation a me nā ʻōnaehana fibrinolytic, ua ʻike pū ʻia e kōkua nui i ka hoʻoponopono ʻana i ka ʻeha.Ma ka wehewehe ʻana, ʻo ka fibrinolysis kahi kaʻina olaola paʻakikī e hilinaʻi ana i ka hoʻāla ʻana o kekahi mau enzyme e hāpai i ka hōʻino ʻana o ka fibrin.Ua manaʻo ʻia ka hopena fibrinolysis e nā mea kākau ʻē aʻe e hiki i nā huahana hoʻohaʻahaʻa fibrin (fdp) ke lilo i mau mea molekala ke kuleana no ka hoʻoulu ʻana i ka hoʻoponopono kino.ʻO ke kaʻina o nā hanana koʻikoʻi koʻikoʻi ma mua mai ka waiho ʻana o ka fibrin a me ka wehe ʻana o ka angiogenesis, pono ia no ka ho'ōla ʻana i ka ʻeha.ʻO ka hoʻokumu ʻana o nā clots ma hope o ka hōʻeha he mea ia e pale aku ai i nā ʻiʻo mai ke kahe o ke koko a me ka hoʻouka ʻana o nā microbial agents, a hāʻawi pū i kahi matrix pōkole e hiki ai i nā cell ke neʻe i ka wā o ka hana hoʻoponopono.Ma muli o ka hoʻokaʻawale ʻana o ka fibrinogen e ka serine protease, a ʻohi ʻia nā platelets i loko o ka mesh fibrin fiber mesh.Hoʻomaka kēia hopena i ka polymerization o ka monomer fibrin, ʻo ia ka hanana nui o ka hoʻokumu ʻana i ke koko.Hiki ke hoʻohana ʻia ka clot ma ke ʻano he waihona o nā cytokines a me nā mea ulu, i hoʻokuʻu ʻia i ka wā o ka degranulation o nā platelets i hoʻāla ʻia.Hoʻoponopono paʻa ʻia ka ʻōnaehana fibrinolytic e ka plasmin, a he hana koʻikoʻi i ka hoʻolaha ʻana i ka neʻe ʻana o nā cell, ka bioavailability o nā mea ulu a me ka hoʻoponopono ʻana i nā ʻōnaehana protease ʻē aʻe e pili ana i ka ʻāʻī a me ka hana hou.ʻO nā mea nui o ka fibrinolysis, e like me ka urokinase plasminogen activator receptor (uPAR) a me ka plasminogen activator inhibitor-1 (PAI-1), ua ʻike ʻia e hōʻike ʻia i nā mesenchymal stem cell (MSCs), ʻo ia nā ʻano cell kūikawā e pono ai no ka hoʻōla ʻana i ka ʻeha. .

 

Ka neʻe ʻana o ke kelepona

ʻO ka hoʻouluʻana o ka plasminogen ma o ka hui uPA uPAR kahi hana e hoʻoikaika ai i ka neʻeʻana o nā pūnaewele inflammatory no ka mea e hoʻonui i ka proteolysis extracellular.Ma muli o ka nele o ka transmembrane a me nā kikowaena intracellular, pono ka uPAR i nā mea hoʻokipa e like me ka integrin a me ka vitellin e hoʻoponopono i ka neʻe ʻana o ke kelepona.Ua hōʻike hou aku ʻo ka hoʻopaʻa ʻana o ka uPA uPAR i hoʻonui i ka pili o ka uPAR no ka virectonectin a me ka integrin, ka mea i hāpai i ka hoʻopili cell.ʻO ka Plasminogen activator inhibitor-1 (PAI-1) ka mea e hoʻokaʻawale nā ​​​​pūnaewele.Ke hoʻopaʻa ʻia i ka uPA o ka uPA upar integrin complex ma ka ʻili o ke kelepona, hoʻopau ia i ka pilina ma waena o upar vitellin a me integrin vitellin.

I loko o ka pōʻaiapili o ka lāʻau lapaʻau hoʻōla hou, hoʻoneʻe ʻia nā pūnaewele mesenchymal stem cell mai ka iwi iwi i ka hihia o ka pōʻino kino nui, no laila hiki ke loaʻa i ke kaʻa ʻana o nā maʻi me nā haʻihaʻi lehulehu.Eia nō naʻe, i nā hihia kikoʻī, e like me ka pau ʻole o ka renal hope, ka pau ʻole o ka ate, a i ka wā o ka hōʻole ʻana ma hope o ka hoʻololi ʻana o ka naʻau, ʻaʻole ʻike ʻia kēia mau cell i ke koko [66].ʻO ka mea mahalo, ʻaʻole hiki ke ʻike ʻia kēia mau iwi iwi iwi mesenchymal (stromal) progenitor cell i ke koko o nā kānaka olakino [67].ʻO ke kuleana o ka uPAR i ka hoʻouluʻana i nā pūpū mesenchymal stem cell (BMSCs) i ka iwi ma mua, ua like ia me ka hanana o ka uPAR i ka hoʻouluʻana o nā pūpū hematopoietic stem cell (HSCs).ʻO Varabaneni et al.Ua hōʻike ʻia nā hopena i ka hoʻohana ʻana o ka granulocyte colony-stimulating factor i ka uPAR deficient mice i hana i ka hemahema MSC, ka mea i hoʻoikaika hou i ke kuleana kākoʻo o ka ʻōnaehana fibrinolysis i ka neʻe ʻana o ke kelepona.Ua hōʻike hou nā haʻawina hou i ka glycosyl phosphatidylinositol i hoʻopaʻa ʻia i ka uPA receptors e hoʻoponopono i ka adhesion, migration, proliferation a me ka hoʻokaʻawale ʻana ma o ka hoʻāla ʻana i kekahi mau ala hōʻailona intracellular, penei: survivable phosphatidylinositol 4,5-diphosphate 3-kinase/Akt a me ERK1/2 ala ala hōʻailona, ​​a adheling kinase. (FAK).

I ka pōʻaiapili o ka hōʻeha ʻeha o MSC, ua hōʻoia ka mea fibrinolytic i kona koʻikoʻi.No ka laʻana, ua hōʻike nā ʻiole plasminogen i ka lohi nui i nā hanana ho'ōla ʻeha, e hōʻike ana he mea nui ka plasmin i kēia hana.I loko o nā kānaka, hiki i ka nalowale o ka plasmin ke alakaʻi i nā pilikia o ka ho'ōla ʻana i ka ʻeha.ʻO ka hoʻopau ʻana i ke kahe ʻana o ke koko e hiki ke kāohi i ka hoʻōla hou ʻana o ka ʻiʻo, ʻo ia hoʻi ka wehewehe ʻana i ke kumu i ʻoi aku ka paʻakikī o kēia mau kaʻina hana hou i nā poʻe maʻi me ka maʻi diabetes.

Ua kiʻi ʻia nā pūnaewele mesenchymal marrow marrow i ka wahi ʻeha e hoʻolalelale i ka hoʻōla ʻana i ka ʻeha.Ma lalo o nā kūlana paʻa, ua hōʻike kēia mau pūnaewele i ka uPAuPAR a me PAI-1.ʻO nā protein hope ʻelua he hypoxia inducible factor α (HIF-1 α) He kūpono loa ka huli ʻana no ka mea HIF-1 i MSCs α ʻO ka hoʻāla ʻana o FGF-2 a me HGF i hāpai i ka hoʻoponopono ʻana o FGF-2 a me HGF;HIF-2 α I ka huli ʻana, VEGF-A [77] ua hoʻoponopono ʻia, e kōkua pū ana i ka ho'ōla ʻana.Eia kekahi, ʻo ka HGF ka mea e hoʻonui ai i ka hoʻoulu ʻana o nā pūpū mesenchymal stem cell i loko o nā wahi ʻeha ma ke ʻano synergistic.Pono e hoʻomaopopo ʻia ua hōʻike ʻia nā kūlana ischemic a me hypoxic e hoʻopilikia nui i ka hoʻoponopono ʻana i ka ʻeha.ʻOiai ke ola nei nā BMSC i loko o nā ʻiʻo e hāʻawi ana i nā pae oxygen haʻahaʻa, ua kaupalena ʻia ke ola ʻana o nā BMSC i hoʻololi ʻia ma vivo no ka mea e make pinepine nā cell transplanted ma lalo o nā kūlana ʻino i ʻike ʻia i nā ʻiʻo i hōʻino ʻia.ʻO ka hopena o ka hoʻopili ʻana a me ke ola ʻana o ka iwi iwi mesenchymal stem cell ma lalo o hypoxia e pili ana i nā mea fibrinolytic i huna ʻia e kēia mau cell.He kiʻekiʻe ka pilina o PAI-1 no ka vitellin, no laila hiki iā ia ke hoʻokūkū no ka hoʻopaʻa ʻana o ka uPAR a me ka integrin i ka vitellin, a laila e pale ai i ka hoʻopili ʻana o ka cell a me ka neʻe ʻana.

PRF

Monocyte and Regeneration System

Wahi a ka moʻolelo, nui nā kūkākūkā e pili ana i ke kuleana o nā monocytes i ka ho'ōla ʻana i ka ʻeha.Loaʻa nā macrophages mai nā monocytes koko a pāʻani i kahi hana koʻikoʻi i ka lāʻau lapaʻau hou [81].Ma muli o ka huna ʻana o nā neutrophils i ka IL-4, IL-1, IL-6 a me TNF-α, Ke komo mau nei kēia mau cell i ka ʻeha ma kahi o 24-48 mau hola ma hope o ka ʻeha.Hoʻokuʻu nā platelets i ka thrombin a me ka platelet factor 4 (PF4), hiki ke hoʻoikaika i ka hoʻoulu ʻana o nā monocytes a hoʻokaʻawale i nā macrophages a me nā cell dendritic.ʻO kahi hiʻohiʻona koʻikoʻi o nā macrophages ko lākou plasticity, ʻo ia hoʻi, hiki iā lākou ke hoʻololi i nā phenotypes a hoʻokaʻawale i nā ʻano cell ʻē aʻe, e like me nā cell endothelial, a laila hōʻike i nā hana like ʻole i nā mea hoʻoulu biochemical ʻokoʻa i ka microenvironment ʻeha.Hōʻike nā pūnaewele inflammatory ʻelua phenotypes nui, M1 a i ʻole M2, ma muli o ka hōʻailona molekala kūloko ma ke ʻano he kumu hoʻoulu.Hoʻokomo ʻia nā macrophages M1 e nā microbial agents, no laila ʻoi aku ka nui o nā hopena proinflammatory.I ka hoʻokaʻawale ʻana, hana pinepine ʻia nā macrophages M2 e nā ʻano ʻano 2 a loaʻa nā waiwai anti-inflammatory, maʻamau i hōʻike ʻia e ka piʻi ʻana o IL-4, IL-5, IL-9, a me IL-13.Hoʻopili pū ʻia i ka hoʻoponopono ʻana i nā kiko ma o ka hana ʻana i nā mea ulu.ʻO ka hoʻololi ʻana mai M1 a i M2 subtype ke alakaʻi nui ʻia e ka hopena hope o ka ho'ōla ʻana i ka ʻeha.Hoʻomaka ka M1 macrophages i ka neutrophil apoptosis a hoʻomaka i ka hoʻomaʻemaʻe o kēia mau cell).Hoʻoulu ka phagocytosis o neutrophils i nā hanana, kahi i hoʻopau ʻia ai ka hana ʻana o nā cytokines, polarizing macrophages a hoʻokuʻu i ka TGF-β 1. ʻO kēia mea ulu he mea hoʻoponopono kiʻi o ka myofibroblast differentiation a me ka ʻeha ʻeha, e ʻae ai i ka hoʻonā ʻana o ka mumū a me ka ʻeha. ka hoʻomaka o ka proliferation phase i ka ho'ōla cascade [57].ʻO kekahi pūmua pili loa e pili ana i nā kaʻina cellular he serine (SG).Ua ʻike ʻia kēia hemopoietic cell secretory granule proteoglycan he pono no ka mālama ʻana i nā protein huna i loko o nā cell immune kikoʻī, e like me nā mast cell, neutrophils a me cytotoxic T lymphocytes.ʻOiai ʻo ka nui o nā pūnaewele hematopoietic ʻole e synthesize i ka plasminogen, hoʻopuka nā cell inflammatory āpau i ka nui o kēia protein a mālama i loko o nā granules no ka launa pū ʻana me nā mea hoʻomohala ʻē aʻe, me nā proteases, cytokines, chemokines a me nā kumu ulu.ʻO nā kaulahao glycosaminoglycan (GAG) i hoʻopiʻi ʻia ma SG he mea koʻikoʻi ia i ka paʻa o nā granules huna, no ka mea hiki iā lākou ke hoʻopaʻa a hoʻomaʻamaʻa i ka mālama ʻana i nā mea kikoʻī i hoʻopaʻa ʻia i loko o ke kelepona, protein, a me ke kaulahao GAG.E pili ana i ko lākou komo ʻana i ka noiʻi PRP, ua hōʻike mua ʻo Woulfe a me nā hoa hana i ka hemahema o SG e pili kokoke ana i nā loli morphological platelet;Platelet factor 4 β- Nā hemahema o ka mālama ʻana o PDGF i ka thromboglobulin a me nā platelets;ʻAʻole maikaʻi ka platelet aggregation a me ka huna ʻana i loko o ka vitro a me ka thrombosis defect in vivo.No laila ua hoʻoholo nā mea noiʻi ʻo kēia proteoglycan ka mea hoʻoponopono nui o ka thrombosis.

Fibrinolytic

Hiki i nā huahana waiwai platelet ke loaʻa i ke koko holoʻokoʻa pilikino ma o ka hōʻiliʻili ʻana a me ka centrifugation, a hoʻokaʻawale i ka hui ʻana i nā papa like ʻole i loko o ka plasma, platelets, nā keʻokeʻo keʻokeʻo a me nā keʻokeʻo keʻokeʻo.Ke kiʻekiʻe ka pae platelet ma mua o ka waiwai kumu, hiki iā ia ke hoʻolalelale i ka ulu ʻana o ka iwi a me nā ʻiʻo palupalu, me nā hopena liʻiliʻi loa.ʻO ka hoʻohana ʻana i nā huahana PRP autologous he biotechnology hou, i hōʻike mau i nā hopena maikaʻi i ka hoʻoulu ʻana a me ka hoʻomaikaʻi ʻana i ka hoʻōla ʻana i nā ʻeha ʻeha like ʻole.ʻO ka maikaʻi o kēia ʻano hana lapaʻau ʻē aʻe e pili ana i ka lawe ʻana i kahi ākea o nā kumu ulu a me nā protein e hoʻohālikelike a kākoʻo i ka hoʻōla ʻana i ka ʻeha physiological a me ke kaʻina hana hoʻoponopono.Eia kekahi, he mea koʻikoʻi ka ʻōnaehana fibrinolytic i ka hoʻoponopono ʻana o ka ʻiʻo holoʻokoʻa.Ma waho aʻe o ka hoʻololi ʻana i ka hoʻopaʻa ʻana o nā cell inflammatory a me ka iwi iwi mesenchymal stem cell, hiki iā ia ke hoʻoponopono i ka hana proteolytic o nā wahi ho'ōla ʻeha a me ke kaʻina hana hou o nā ʻiʻo mesodermal, me ka iwi, cartilage a me ka ʻiʻo, no laila he mea nui ia o ka. lāʻau musculoskeletal.

ʻO ka ho'ōla wikiwiki ka pahuhopu i ʻimi nui ʻia e nā poʻe loea he nui i ka ʻoihana lapaʻau.Hōʻike ka PRP i kahi mea hana olaola maikaʻi, e hoʻomau nei i ka hoʻomohala ʻana i ka hoʻoulu ʻana a me ka hoʻonohonoho ʻana i ka cascade o nā hanana regenerative.Eia nō naʻe, no ka mea paʻakikī loa kēia mea lapaʻau, ʻoi aku ka nui o ka hoʻokuʻu ʻana i nā mea bioactive he nui a me kā lākou mau ʻano hana like ʻole a me nā hopena transduction hōʻailona, ​​​​pono e noiʻi hou.

(Paʻi hou ʻia nā mea o kēia ʻatikala, ʻaʻole mākou e hāʻawi i ka hōʻoiaʻiʻo a i ʻole ka hōʻoia ʻana no ka pololei, hilinaʻi a i ʻole ka piha o nā mea i loko o kēia ʻatikala, a ʻaʻole kuleana no nā manaʻo o kēia ʻatikala, e ʻoluʻolu e hoʻomaopopo.)


Ka manawa hoʻouna: Dec-16-2022